文献速递浆细胞疾病

内皮素-1受体阻断作为多发性骨髓瘤新的可能治疗途径

Endothelin-1 receptor blockade as new possible therapeutic approach in multiple myeloma.
PubMed 文献 · Br J Haematol · 2017-06-09

多发性骨髓瘤(MM)需要新的有效治疗,浆细胞限制性表达的受体是有吸引力的靶点。研究发现MM细胞系和原代恶性浆细胞高表达EDNRB并释放EDN1,骨髓微环境细胞也分泌EDN1;健康供者浆细胞或B淋巴细胞存在EDNRB启动子高甲基化和基因下调。双EDN1受体拮抗剂波生坦降低U266和RPMI-8226细胞活力及MAPK活化,与硼替佐米联用产生协同细胞毒效应,支持EDN1受体作为MM新治疗靶点。

要点

  • MM细胞系和原代恶性浆细胞高表达EDNRB并释放EDN1,骨髓微环境细胞也分泌EDN1。
  • 健康供者浆细胞或B淋巴细胞中EDNRB启动子高甲基化并伴EDNRB基因下调。
  • 波生坦降低U266和RPMI-8226细胞活力及MAPK活化,与硼替佐米联用有协同细胞毒效应。

核心结论

  • 数据揭示EDN1介导的自分泌和旁分泌机制调控恶性浆细胞生长和药物反应,支持EDN1受体作为MM新治疗靶点。

研究设计与样本

  • 研究检测MM细胞系和原代恶性浆细胞中EDN1轴表达,并分析EDNRB基因表观遗传调控。
  • 研究用双EDN1受体拮抗剂波生坦处理U266和RPMI-8226细胞,并评估与硼替佐米联用的效应。

主要发现

  • 除EDNRA外,多数MM细胞系和原代恶性浆细胞高表达EDNRB并释放EDN1,骨髓微环境细胞也分泌EDN1。
  • 健康供者浆细胞或B淋巴细胞中观察到EDNRB启动子高甲基化和EDNRB基因下调,而表达EDNRB的恶性浆细胞无此表现。
  • 波生坦降低U266和RPMI-8226细胞活力和MAPK活化。
  • 波生坦与硼替佐米联用产生协同细胞毒效应。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

New effective treatments are needed to improve outcomes for multiple myeloma (MM) patients. Receptors with restricted expression on plasma cells (PCs) represent attractive new therapeutic targets. The endothelin-1 (EDN1) axis, consisting of EDN1 acting through EDN-receptor A (EDNRA) and B (EDNRB), was previously shown to be overexpressed in several tumours, including MM. However, there is incomplete understanding of how EDN1 axis regulates MM growth and response to therapy. Besides EDNRA, the majority of MM cell lines and primary malignant PCs express high levels of EDNRB and release EDN1. Similarly, bone-marrow microenvironment cells also secrete EDN1. Investigating the extent of epigenetic dysregulation of EDNRB gene in MM, we found that hypermethylation of EDNRB promoter and subsequent down-regulation of EDNRB gene was observed in PCs or B lymphocytes from healthy donors compared to EDNRB-expressing malignant PCs. Pharmacological blockade with the dual EDN1 receptor antagonist bosentan decreased cell viability and MAPK activation of U266 and RPMI-8226 cells. Interestingly, the combination of bosentan and the proteasome inhibitor bortezomib, currently approved for MM treatment, resulted in synergistic cytotoxic effects. Overall, our data has uncovered EDN1-mediated autocrine and paracrine mechanisms that regulate malignant PCs growth and drug response, and support EDN1 receptors as new therapeutic targets in MM.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Russignan A, Spina C, Tamassia N, et al. Endothelin-1 receptor blockade as new possible therapeutic approach in multiple myeloma. Br J Haematol. 2017. PMID: 28597546. doi:10.1111/bjh.14771

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。